Bioventus Inc is a medical devices business based in the US. Bioventus Inc shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.59 – an increase of 3.85% over the previous week. Bioventus Inc employs 1,030 staff and has a trailing 12-month revenue of around $555.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.59 |
|---|---|
| 52-week range | $3.67 - $14.38 |
| 50-day moving average | $11.90 |
| 200-day moving average | $7.48 |
| Wall St. target price | $14.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.61 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.25 from 2024-11-18
| 1 week (2024-11-12) | -4.98% |
|---|---|
| 1 month (2024-10-18) | -13.13% |
| 3 months (2024-08-19) | 40.63% |
| 6 months (2024-05-17) | 76.33% |
| 1 year (2023-11-17) | 193.73% |
|---|---|
| 2 years (2022-11-18) | 492.11% |
| 3 years (2021-11-19) | 14.02 |
| 5 years (2019-11-16) | N/A |
Valuing Bioventus Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bioventus Inc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus Inc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bioventus Inc's PEG ratio in relation to those of similar companies.
Bioventus Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $50.4 million.
The EBITDA is a measure of a Bioventus Inc's overall financial performance and is widely used to measure a its profitability.
To put Bioventus Inc's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $555.1 million |
|---|---|
| Operating margin TTM | 4.78% |
| Gross profit TTM | $302.7 million |
| Return on assets TTM | 2.48% |
| Return on equity TTM | -24.76% |
| Profit margin | -7.11% |
| Book value | $2.28 |
| Market Capitalization | $727.5 million |
TTM: trailing 12 months
We're not expecting Bioventus Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Bioventus Inc's shares have ranged in value from as little as $3.67 up to $14.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bioventus Inc's is 0.88. This would suggest that Bioventus Inc's shares are less volatile than average (for this exchange).
To put Bioventus Inc's beta into context you can compare it against those of similar companies.
Bioventus Inc. , a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.